| 英文名 | 2-{(3S)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide |
|---|---|
| 英文别名 |
2H-1,4-Benzoxazine-3-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)carbonyl]-7-fluoro-3,4-dihydro-N-methyl-, (3S)-
2-{(3S)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide |
| 描述 | AZD9977是一种新型,一流,选择性和口服盐皮质激素受体(MR)调节剂,pKi为7.5,对GR,PR和AR几乎没有亲和力(pIC50<5.5)；剂量依赖性降低白蛋白尿并改善肾脏组织病理学类似于db/db单肾切除小鼠和单肾切除大鼠中的依普利酮,不影响尿Na+/K+比率。糖尿病1期临床 |
|---|---|
| 参考文献 | References 1. Bamberg K, et al. PLoS One. 2018 Feb 23;13(2):e0193380. 2. Erlandsson F, et al. Br J Clin Pharmacol. 2018 Feb 21. doi: 10.1111/bcp.13562. View Related Products by Target Mineralocorticoid Receptor (MLR) Diabetes |
| 密度 | 1.4±0.1 g/cm3 |
|---|---|
| 沸点 | 731.4±60.0 °C at 760 mmHg |
| 分子式 | C20H18FN3O5 |
| 分子量 | 399.372 |
| 闪点 | 396.1±32.9 °C |
| 精确质量 | 399.123047 |
| LogP | 0.00 |
| 蒸汽压 | 0.0±2.4 mmHg at 25°C |
| 折射率 | 1.597 |
